[New aspects on "triple therapy" after coronary stent implantation].

Antithrombotic/antiplatelet therapy after coronary stent implantation is recommended with a high level of evidence in international guidelines. However, antithrombotic/antiplatelet treatment in patients after coronary stent implantation and in addition with an indication for oral anticoagulation is still an open issue. So called "tripletherapy", the combination of oral anticoagulation with vitamin K-antagonists, clopidogrel and aspirin, is commonly used. This combination significantly increases incidence of minor and major bleedings, especially during long term use. The goal of this manuscript is to discuss the risks and potential benefit of "tripletherapy" in patients with an indication for oral anticoagulation after coronary stent implantation. © Georg Thieme Verlag KG Stuttgart · New York.